Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v15.i6.20
41 pages

Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers

Joseph A. Reddy
Department of Chemistry, Purdue University, West Lafayette, IN 47907-1393
Philip S. Low
Department of Chemistry, Purdue University, West Lafayette, IN 47907-1393


The vitamin folic acid (FA) enters cells either through a carrier protein, termed the reduced folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor (FR). Because folate-drug conjugates are not substrates of the former, they penetrate cells exclusively via FR-mediated endocytosis. When FA is covalently linked via its γ-carboxyl to a drug or imaging agent, FR binding affinity (KD ~ 10−10 M) is not measurably compromised, and endocytosis proceeds relatively unhindered, promoting uptake of the attached drug/imaging agent by the FR-expressing cell. Because FRs are significantly overexpressed on a large fraction of human cancer cells (e.g., ovarian, lung, breast, endometrial, renal, colon, and cancers of myeloid hematopoietic cells), this methodology may allow for the selective delivery of a wide range of imaging and therapeutic agents to tumor tissue. Folate-mediated tumor targeting has been exploited to date for delivery of the following molecules and molecular complexes: (i) protein toxins, (ii) low-molecular-weight chemotherapeutic agents, (iii) radioimaging agents, (iv) MRI contrast agents, (v) radiotherapeutic agents, (vi) liposomes with entrapped drugs, (vii) genes, (viii) antisense oligonucleotides, (ix) ribozymes, and (x) immunotherapeutic agents. In virtually all cases, in vitro studies demonstrate a significant improvement in potency and/or cancer-cell specificity over the nontargeted form of the same pharmaceutical agent. Where live animal studies have been conducted, they also reveal significant promise.

Articles with similar content:

Vitamin B12-Mediated Transport: A Potential Tool for Tumor Targeting of Antineoplastic Drugs and Imaging Agents
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 4
Yashwant Gupta, Dharm Veer Kohli, Sanjay Kumar Jain
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Sathish Dyawanapelly, Animesh Kumar, Manish K. Chourasia
Steroid Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 3
Vandana Soni, Piush Khare, Suresh P. Vyas, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain, Pramod Mishra
From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.15, 1998, issue 2
Alain P. Rolland
Multinucleated Osteoclast Formation In Vivo and In Vitro by P2X7 Receptor-Deficient Mice
Critical Reviews™ in Eukaryotic Gene Expression, Vol.13, 2003, issue 2-4
Robert A. Hipskind, James A. Gallagher, G. Buell, Katherine A. Buckley, Wayne B. Bowler, Alison Gartland, I. Chessell, J. H. Tobias, M. J. Perry